Our Team
Our team brings together expertise in bioengineering, regenerative medicine, and translational science, united by a shared mission: to transform the future of heart repair.
Eric van der Veer
Chief Executive OfficerEric leads Ibnova’s operational execution in Denmark, drawing on prior experience building and leading a company as CEO. He is responsible for program delivery across budgets, timelines, contracts, and external partners, helping de-risk execution and convert technical milestones into a financeable, investable company.
Andrew Laskary
Co-Founder, Executive Director
& Chief Scientific OfficerAndrew is a clinician-scientist trainee and lead developer of the Vascular Heart Patch. He drives Ibnova’s scientific vision, product architecture, and translational strategy. He leads the integration of science, clinical positioning, regulatory planning, company governance, and partnerships to ensure the platform is designed not only for efficacy, but for clinical adoption and commercial scalability.
Ian Fernandes
Chief Technology Officer & Lead Cell Therapy ScientistIan leads technical development of Ibnova’s manufacturing platform, with expertise in vascular and cardiac cell therapy processes. He is responsible for process development, process locking, materials qualification, technology transfer readiness, and the analytical and documentation frameworks required to de-risk manufacturing and enable reproducible scale-up.
James Hudson
Co-Founder & Scientific AdvisorJames provides strategic scientific oversight across product and platform development, bringing leading expertise in stem cell cardiac tissue engineering. He supports key design decisions, translational rigor, and the development of performance assays that demonstrate consistency, mechanism, and therapeutic relevance as the platform advances.
Enzo Porrello
Co-Founder and Scientific AdvisorEnzo brings globally recognized expertise in cardiac stem cell biology and regeneration to support the biological design of Ibnova’s platform. He advises on the mechanistic rationale underpinning patch composition, the selection of biologically meaningful readouts, and the broader strategy to de-risk translation toward the clinic.
